Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025338 | 1.00 | CA1 (0.39) | CA1CA2CA9ACHEPTGS1 | |
| SCHEMBL2800774 | 1.00 | CA1 (0.39) | CA1CA2CA9ACHEPTGS1 | |
| SCHEMBL2801374 | 0.91 | ACHE (0.51) | ACHEBCHEFAAH | |
| SCHEMBL1825973 | 0.87 | CA1 (0.39) | CA1CA2CA9ACHEPTGS1 | |
| SCHEMBL1826052 | 0.83 | CYP19A1 (0.36) | CA1CA2CA9ACHEPTGS1 | |
| SCHEMBL2799811 | 0.82 | ACHE (0.57) | ACHEBCHEFAAH | |
| SCHEMBL2026891 | 0.82 | ACHE (0.57) | ACHEBCHEFAAH | |
| SCHEMBL2026893 | 0.82 | ACHE (0.57) | ACHEBCHEFAAH | |
| SCHEMBL16726991 | 0.81 | SLC6A4 (0.43) | — | |
| SCHEMBL1826835 | 0.81 | ACHE (0.40) | ACHEPTGS1ALDH1A1BCHEFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415508-B2 | Process for the preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | claimed |
| US-20100168229-A1 | Process for the preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | claimed |
| US-8637713-B2 | Process for preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2014-01-28 | — | — | US | disclosed |
| US-20130096337-A1 | Process for Preparation of Optically Active Compounds using Transfer Hydrogenation | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-8415508-B2 | Process for the preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| US-8415508-B2 | Process for the preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| WO-2011073362-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE COMPOUNDS USING PRESSURE HYDROGENATION | NOVARTIS AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20100168229-A1 | Process for the preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100168229-A1 | Process for the preparation of optically active compounds using transfer hydrogenation | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096337-A1 | Process for Preparation of Optically Active Compounds using Transfer Hydrogenation | SPR, ACHE, QDPR | CA1 1683/4885CA2 3232/4885CA9 2512/4885 |
| US-20100168229-A1 | Process for the preparation of optically active compounds using transfer hydrogenation | SPR, ACHE, QDPR | CA1 1670/4885CA2 3091/4885CA9 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.